Who
Rakhi Kumar
Director
Company insider
Files Form 4 as: Director, Neuropace; Chief Accounting Officer, Roivant Sciences.
In numbers
- Trades disclosed
- 121
- Buys
- 0
- Sells
- 25
- Bought
- $0
- Sold
- $9.9M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 21 Apr 2021
- Last trade
- 19 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Jun 2026filed 22 Jun 2026 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K989 at $15.63 | filing |
| 19 Jun 2026filed 22 Jun 2026 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K989 at $15.63 | filing |
| 5 Jun 2026filed 5 Jun 2026 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | —2,890 at $0.00 | filing |
| 5 Jun 2026filed 5 Jun 2026 | NPCE Neuropaceoption or derivative · Medical Devices | SEC FORM 4 Code A | —5,368 at $0.00 | filing |
| 5 Jun 2026filed 5 Jun 2026 | NPCE Neuropaceoption or derivative · Medical Devices | SEC FORM 4 Code A | —5,368 at $0.00 | filing |
| 5 Jun 2026filed 5 Jun 2026 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | —2,890 at $0.00 | filing |
| 20 Mar 2026filed 23 Mar 2026 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K1,153 at $13.00 | filing |
| 20 Mar 2026filed 23 Mar 2026 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K1,153 at $13.00 | filing |
| 19 Dec 2025filed 23 Dec 2025 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K904 at $16.59 | filing |
| 19 Sep 2025filed 22 Sep 2025 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K1,509 at $9.94 | filing |
| 21 Jun 2025filed 24 Jun 2025 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K1,440 at $10.41 | filing |
| 6 Jun 2025filed 9 Jun 2025 | NPCE Neuropaceoption or derivative · Medical Devices | SEC FORM 4 Code A | —8,745 at $0.00 | filing |
| 21 Mar 2025filed 24 Jun 2025 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K1,247 at $12.02 | filing |
| 20 Feb 2025filed 24 Feb 2025 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $10K958 at $10.72 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —187,500 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $722K187,500 at $3.85 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $2.4M227,500 at $10.43 | filing |
| 20 Jan 2025filed 22 Jan 2025 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $12K1,057 at $11.15 | filing |
| 21 Dec 2024filed 24 Jun 2025 | NPCE NeuropaceMedical Devices | SEC FORM 4 Code A | $15K1,300 at $11.53 | filing |
| 20 Dec 2024filed 26 Dec 2024 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $36K3,087 at $11.57 | filing |
News
Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RiseROIV · rttnews.com · 21 Oct 2026Head to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR)ROIV · dailypolitical.com · 14 Oct 2026Analyzing Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS)ROIV · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Rakhi Kumar; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.